Regulation of Insulin Receptor Substrate-2 Tyrosine Phosphorylation in Animal Models of Insulin Resistance
Abstract
Insulin induces a wide variety of growth and metabolic responses in many cell types. These actions are initiated by insulin binding to its receptor and involve a series of alternative and complementary pathways created by the multiple substrates of the insulin receptor (insulin receptor substrates [IRSs]). We investigated IRS-1 and IRS-2 tyrosine phosphorylation; their association with phosphatidylinositol-3-OH kinase (PI3-K); and the phosphorylation of Akt, a serine-threonine kinase situated downstream of PI3-K, in liver and muscle of two animal models of insulin resistance: epinephrine- or dexamethasone-treated rats. We used in vivo insulin infusion followed by tissue extraction, immunoprecipitation, and immunoblotting. IRS-1 and IRS-2 protein expression did not change in liver and muscle of the epinephrine- treated rats, but in dexamethasone-treated rats IRS-1 presented an increase in liver and a decrease in muscle tissue. PI3-K and Akt protein expression did not change in liver or muscle of the two animal models of insulin resistance. There was a downregulation in insulin- induced IRS-1 and IRS-2 tyrosine phosphorylation and association with PI3-K in both models of insulin resistance. In parallel, insulin-induced Akt phosphorylation was reduced in both tissues of epinephrine-treated rats, and in liver but not in muscle of dexamethasonetreated rats. The reduction in insulin-induced Akt phosphorylation may help to explain the insulin resistance in liver and muscle of epinephrine-treated rats and in the liver of dexamethasone-treated rats.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GCs were shown to interfere with insulin signalling in vitro and in vivo in rodents in liver, adipose tissue and skeletal muscle.
“GCs were shown to interfere with insulin signalling in vitro and in vivo in rodents in liver [38], adipose tissue [39] and skeletal muscle [40].”
From Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial (2011) · cites this paper as [38]
Cites
Saad, M. J., Folli, F., Kahn, J. A., & Kahn, C. R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116803 · Cited by 349 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2174-9 · Cited by 109 · see citing works
“GCs were shown to interfere with insulin signalling in vitro and in vivo in rodents in liver [38], adipose tissue [39] and skeletal muscle [40].”
BackgroundTomlinson, J. W., Finney, J., Hughes, B. A., Hughes, S. V., & Stewart, P. M. (2008) · Diabetes · doi:10.2337/db08-0094 · Cited by 91 · see citing works
Glucocorticoid Modulation of Insulin Signaling in Human Subcutaneous Adipose Tissue
Gathercole, L. L., Bujalska, I. J., Stewart, P. M., & Tomlinson, J. W. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1399 · Cited by 73 · see citing works
Fox, A. S., Oler, J. A., Shelton, S. E., Nanda, S. A., Davidson, R. J., Roseboom, P. H., & Kalin, N. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206723109 · Cited by 57 · see citing works
- Authors
- Rojas, F. A., Hirata, A. E., & Saad, M. J. A.
- Affiliations
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Venue
- Endocrine
- Published
- 2003
- Volume
- 21
- Issue
- 2
- Pages
- 115-122
- ISSN
- 0969-711X (ISSN-L)
- OpenAlex
- W1965984750
- Cited by
- 30
- References
- 1
- Citations by year
- 2026: 1 · 2022: 4 · 2021: 1 · 2020: 1 · 2019: 3 · 2017: 2 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 2
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- insulin receptor substrate 2, IRS-1, tyrosine phosphorylation, insulin resistance, phosphatidylinositol 3-kinase, Akt phosphorylation, epinephrine, dexamethasone, liver, skeletal muscle, insulin signaling
- MeSH terms
- Animals, Dexamethasone, Disease Models, Animal, Epinephrine, Insulin Resistance, Liver, Male, Phosphoproteins, Phosphorylation, Proto-Oncogene Proteins, Tyrosine, Down-Regulation, Rats, Wistar, Protein Serine-Threonine Kinases, Muscle, Skeletal, Phosphatidylinositol 3-Kinases, Intracellular Signaling Peptides and Proteins, Proto-Oncogene Proteins c-akt, Rats, Insulin Receptor Substrate Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review